RE:It' could be that they are waiting for---
As of May 30:
The maintenance study treatment (so, the 2nd dose) has been provided to 15 patients, with 11 maintenance study treatments pending
30%-50% of these 11 pending would probably give us a clearer picture of the 270-days efficacy % and would allow us to see a clearer trend.
Note also this, as a global perspective, for what's coming up toward the end of 2022:
In 2021, Theralase® completed its first significant milestone of Study II by enrolling and treating 25 patients. The Company will compile a clinical data report for submission to the FDA in support of the grant of a BTD approval after completion of the 450 day assessment for 25 patients, expected in 4Q2022, subject to the Clinical Study Sites (“CSS”) availability to complete all required assessments.